Ertapenem (Invanz)
A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.
Also Known As:
Invanz; Ertapenem Sodium; Invanoz; (4R,5R,6S)-3-((3S,5S)-5-((3-Carboxyphenyl)carbamoyl)pyrrolidin-3-yl)sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
Networked: 539
relevant articles (86 outcomes,
135 trials/studies)
Relationship Network
Drug Context: Research Results
Experts
1. | Woods, Gail L:
19 articles
(06/2004 - 01/2002)
|
2. | Abramson, Murray A:
11 articles
(04/2009 - 08/2005)
|
3. | Teppler, Hedy:
11 articles
(08/2005 - 01/2002)
|
4. | Gesser, Richard M:
11 articles
(06/2004 - 01/2002)
|
5. | Hsueh, Po-Ren:
9 articles
(06/2022 - 05/2011)
|
6. | Ko, Wen-Chien:
9 articles
(06/2022 - 11/2010)
|
7. | Nicolau, David P:
9 articles
(01/2022 - 01/2005)
|
8. | Goldstein, Ellie J C:
9 articles
(04/2009 - 04/2002)
|
9. | Citron, Diane M:
8 articles
(04/2009 - 04/2002)
|
10. | Lipsky, Benjamin A:
7 articles
(01/2020 - 06/2004)
|
Related Diseases
Related Drugs and Biologics
Related Therapies and Procedures